In this episode (20.34 minutes), Medicom’s correspondent covers 6 presentations from the Annual Meeting of the American Academy of Neurology (AAN 2022), held in Seattle (WA, US) from 2-7 April 2022.
The topics discussed are:
- Ravulizumab in patients with generalised myasthenia gravis
In the randomised, phase 3 CHAMPION MG trial, the terminal complement component 5 (C5) inhibitor ravulizumab provided rapid and sustained symptomatic improvements in patients with generalised myasthenia gravis (gMG) for up to 26 weeks. These effects were sustained after an additional 26 weeks of open-label treatment. - IPX203 versus immediate release carbidopa-levodopa
The RISE-PD study compared the safety and efficacy of IPX203 with immediate release carbidopa-levodopa (CD-LD) in Parkinson’s disease patients with motor fluctuations. IPX203, an investigational oral extended-release (ER) formulation of CD-LD, resulted in statistically significant improvement in “good on” time versus immediate release CD-LD, while requiring fewer daily dosages. - Targeting senescent cells to treat age-related diseases
How to target ageing? By clearing the brain of senescent cells, according to Dr Miranda Orr. Senolytics, including the combination of dasatinib plus quercetin, are therapeutic agents that can induce the death of senescent cells. The phase 2 trial StoMP-AD is now enrolling participants to investigate targeting senescent cells to treat Alzheimer’s Disease (AD). - Possible first ever treatment of Rett syndrome
A placebo-controlled, phase 3 study demonstrated that trofinetide is efficacious and has an acceptable safety profile in girls and women with Rett syndrome (RTT). Trofinetide could become the first-ever licensed treatment of RTT. - Ublituximab versus teriflunomide in relapsing Multiple sclerosis patients
In both the phase 3 ULTIMATE I and ULTIMATE II trial, ublituximab treatment demonstrated a statistically significant reduction in annualised relapse rate (ARR) and cumulative probability of first relapse compared with teriflunomide over a 96-week period. - Brain implant helps paralysed patients to communicate
In a first-in-human study, 4 completely paralysed patients with Amyotrophic lateral sclerosis (ALS) had a brain-computer interface (BCI) implanted. This so-called endovascular motor neuroprosthesis (MNP) was safe and allowed patients to control a computer by thought, so they could send emails, browse the web and, in one case, write a book.
Enjoy listening!
Posted on
Previous Article
« Once-daily triple combination pill may best usual care for high blood pressure Next Article
ACC 2022 Highlights Podcast »
« Once-daily triple combination pill may best usual care for high blood pressure Next Article
ACC 2022 Highlights Podcast »
Table of Contents: AAN 2022
Featured articles
Letter from the Editor
Interview with Prof. Natalia Rost
Alzheimer’s Disease and Other Dementias
Targeting senescent cells to treat age-related diseases
Cardiorespiratory fitness protects against dementia
Safety and effects of bosutinib in Lewy body dementia
Epilepsy
“Women with epilepsy should be encouraged to breastfeed”
Fenfluramine: possible new treatment for Lennox-Gastaut syndrome
Laser interstitial thermal therapy for refractory epilepsy
Migraine
Migraine may be an important obstetric risk factor
Intranasal zavegepant safe and well tolerated in healthy adults
Telemedicine during COVID-19 pandemic highly appreciated
Multiple Sclerosis
Ublituximab versus teriflunomide in relapsing MS patients
Ketogenic diet may improve disability and quality of life
Favourable additional safety data for ofatumumab
Predicting new T2 lesions using a machine learning algorithm
Evobrutinib reduces volume of slowly expanding lesions
Sustained long-term efficacy and safety of satralizumab in NMOSD
Muscle and Neuro-Muscular Disorders
Ravulizumab in patients with generalised myasthenia gravis
Gene therapy effective in older patients with spinal muscular atrophy
Losmapimod for facioscapulohumeral muscular dystrophy
SRP-9001 for treating patients with Duchenne muscular dystrophy
Cerebrovascular Disease and Stroke
Intravenous thrombolysis after ischaemic stroke: When in doubt, leave it out?
Better outcomes with mechanical thrombectomy in elderly stroke patients
Plasma NfL levels associated with cardiovascular risk
Non-invasive vagus nerve stimulation for acute stroke
Parkinson’s Disease
Prasinezumab in Parkinson’s disease: delayed-start analysis of PASADENA trial
IPX203 versus immediate release carbidopa-levodopa
Impact of COVID-19 public health interventions
COVID-19
Cognitive, EEG, and MRI features in COVID-19 survivors
Neurological manifestations of COVID-19 worsen prognosis
New evidence for biological basis of “COVID-19 brain fog”
Related Articles
June 16, 2021
Stroke uncommon in critically ill COVID-19 patients
June 16, 2021
Chemosensory dysfunction often persistent after COVID-19
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com